Screener
Edgewise Therapeutics, Inc. EWTX Business Segments — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Personnel expense | 14,725 | 10,624 |
| Stock-based compensation expense | 8,715 | 9,059 |
| Other segment expense(a) | 6,196 | 4,464 |
| Depreciation | 537 | 514 |
| Segment net loss | (54,115) | (45,959) |
| Reconciliation of net loss | ||
| Interest income | 5,102 | 5,161 |
| Net Loss | $(49,013) | $(40,798) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s business segments — operating income?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — operating income of -$54.12M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s business segments — operating income changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — operating income decreased by 17.7% year-over-year, from -$45.96M to -$54.12M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — operating income?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — operating income has grown at a 29.4% compound annual growth rate (CAGR), from -$114.36M to -$191.41M.
- What does business segments — operating income mean?
- Measures the profitability of the company's core business operations by subtracting operating expenses from revenues. For clinical-stage biopharmaceutical companies, this typically represents the cash burn rate associated with R&D and administrative activities. It serves as a primary indicator of the company's operational sustainability before considering financing activities.
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude